We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00154024
First Posted: September 12, 2005
Last Update Posted: September 28, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Technische Universität Dresden
  Purpose
Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.

Condition Intervention
Healthy Subjects Drug: atorvastatin Drug: irbesartan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Characterization of Local Vascular Effects of Angiotensin II and Histamine After Treatment With Irbesartan and Atorvastatin.

Resource links provided by NLM:


Further study details as provided by Technische Universität Dresden:

Primary Outcome Measures:
  • vascular responses after treatment.

Study Start Date: March 2003
Estimated Study Completion Date: October 2006
Detailed Description:
Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy subjects
  • no relevant disease
  • amendment: hypercholesterolaemic subjects

Exclusion Criteria:

  • any relevant disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00154024


Locations
Germany
Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Study Chair: Wilhelm Kirch, MD Institute of Clinical Pharmacology
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00154024     History of Changes
Other Study ID Numbers: IKPD 03-02
First Submitted: September 8, 2005
First Posted: September 12, 2005
Last Update Posted: September 28, 2006
Last Verified: July 2006

Keywords provided by Technische Universität Dresden:
venoconstriction
venodilation
pleiotropic effects

Additional relevant MeSH terms:
Atorvastatin Calcium
Irbesartan
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists